It has been about a month since the last earnings report for Steel Dynamics (STLD) . Shares have added about 0.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Steel Dynamics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.Steel Dynamics’ Q3 Earnings Beat Estimates on ...

A month has gone by since the last earnings report for W.R. Berkley (WRB) . Shares have added about 3.3% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is W.R. Berkley due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.W.R. Berkley Q3 E ...

It has been about a month since the last earnings report for Cleveland-Cliffs (CLF) . Shares have lost about 16.4% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Cleveland-Cliffs due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.C ...

It has been about a month since the last earnings report for Zions (ZION) . Shares have lost about 6.4% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Zions due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Zions Bancorporation, N.A. before we dive into how investors and analysts have reacte ...

Core Insights - Target is focusing on AI partnerships, particularly with OpenAI, to enhance digital tools and improve the shopping experience [1][10] - The company anticipates cautious holiday spending, guiding for a low-single-digit decline in comparable sales [1][7] - Consumers are becoming more selective, prioritizing value and stretching their budgets due to economic pressures [1][4] Financial Performance - In Q3 2025, net sales decreased by 1.5% year-over-year, with comparable sales down 2.7% [3][7] - Comparable digital sales increased by 2.4% [3] - The company experienced volatility in sales trends, with flat results in August and October but a significant decline in September [7] Consumer Behavior - Shoppers are focusing their spending on essentials like food and beauty, while seeking deals in discretionary categories [5] - Consumer sentiment is at a three-year low, influenced by concerns over jobs, affordability, and tariffs [5] - Despite emotional motivations to celebrate the holidays, consumers are intent on avoiding overspending [5] Strategic Initiatives - Target is enhancing its merchandising, customer experience, and technology to better meet consumer demands [6] - The company is leveraging AI for personalized shopping experiences through initiatives like conversational curation [10] - Digital services, including same-day delivery, grew over 35% in the quarter, and AI tools are improving inventory management [11] Category Performance - Food and beverage categories showed growth, with beverages up nearly 7% [8] - Discretionary categories are uneven, with apparel comps down 5%, while toys and video games saw double-digit gains [8]

Coinbase (NASDAQ:COIN) has hired former Goldman Sachs (NYSE:GS) Partner Liz Martin as it looks to expand beyond cryptocurrency trading. Martin is joining Coinbase as vice president of product, overseeing its markets and derivatives divisions, the exchange said in a statement to Benzinga on Thursday. “She will lead Coinbase’s exchanges, drive the next phase of growth for the company’s derivatives business, and manage its global markets team – all key pillars of Coinbase’s ‘Everything Exchange’ strategy,” ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Novartis is expanding its operations in North Carolina by creating a new flagship manufacturing hub with end-to-end manufacturing capabilities, ensuring that key medicines for US patients are produced domestically [1][2][3] - This expansion is part of a larger $23 billion investment in US infrastructure over the next five years, aimed at increasing manufacturing capacity and achieving 100% domestic production of key medicines [2][5] - The new hub is expected to open between 2027 and 2028, covering over 700,000 square feet and creating 700 direct jobs and more than 3,000 indirect jobs by the end of 2030 [3][4] Company Strategy - The flagship hub will consolidate existing and new facilities in North Carolina, enhancing the production of medicines across major therapeutic areas including oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic [2][3] - The proximity of the facilities will facilitate efficient production processes, from manufacturing active ingredients to final packaging [2][4] Economic Impact - The expansion is anticipated to strengthen the local economy and support workforce growth in North Carolina, reinforcing the state's position in advanced pharmaceutical manufacturing [3][4] - Governor Josh Stein highlighted the investment's potential to create skilled jobs and benefit local communities [3]

Core Insights - Novartis is expanding its operations in North Carolina by creating a new flagship manufacturing hub with end-to-end manufacturing capabilities, ensuring that key medicines for US patients are produced domestically [1][2][3] Investment and Infrastructure - The expansion is part of Novartis' $23 billion investment in US-based infrastructure over the next five years, aimed at increasing manufacturing capacity and enabling 100% production of key medicines in the US [2][5] - The new hub will encompass over 700,000 square feet and is expected to create 700 new jobs at Novartis and over 3,000 indirect jobs across the supply chain by the end of 2030 [3][4] Manufacturing Capabilities - The hub will allow for the production of medicines across Novartis' main therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic [2][6] - Existing facilities in Durham will be expanded, and new sites will be built in Morrisville, enhancing capabilities for biologics, sterile packaging, and solid dosage forms [6] Commitment to Innovation - The CEO of Novartis emphasized the commitment to American innovation and the importance of a resilient US supply chain, highlighting the investment's role in delivering medical breakthroughs [3] - North Carolina's leadership in advanced pharmaceutical manufacturing is reinforced by this expansion, which is expected to strengthen the state's economy [3][4]

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.AGIO is testing key support levels. See what the experts say hereThe trial met its primary endpoint of hemoglobin response, with mitapivat demonstrating a statistically significant improvement compared to placebo.Also Read: FDA Delays Decision On Agios Pharmaceuticals’ Blood Disorder Drug For Expanded UseDataWhile mitapivat also showed ...